SCHEMBL2861793

SCHEMBL2861793

O=C(NC1CC1)c1cc2c(-c3cccc(F)c3)n[nH]c2cc1F

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 7/20 0.53
MAP4K4 O95819 3/20 0.51
MAP2K4 P45985 4/20 0.49
GSK3A P49840 1/20 0.48
GSK3B P49841 1/20 0.48
WNT1 P04628 5/20 0.46
MAP2K7 O14733 1/20 0.44
MAP3K5 Q99683 1/20 0.44
LRRK2 Q5S007 1/20 0.44
RIPK1 Q13546 1/20 0.43
MAPK8 P45983 1/20 0.43
KDR P35968 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2866807 0.90 DYRK1A (0.52) DYRK1AMAP4K4MAP2K4GSK3AGSK3B
SCHEMBL2868590 0.87 DYRK1A (0.50) DYRK1AMAP4K4MAP2K4GSK3AGSK3B
SCHEMBL2867207 0.85 KDR (0.48) DYRK1AGSK3BWNT1MAP3K5MAPK8
SCHEMBL2862730 0.83 DYRK1A (0.59) DYRK1AMAP3K5
SCHEMBL2866826 0.82 DYRK1A (0.52) DYRK1AMAP4K4MAP2K4GSK3AGSK3B
SCHEMBL2857674 0.81 MAP2K4 (0.60) MAP2K4GSK3AGSK3BMAP2K7
SCHEMBL4334482 0.81 MAP4K4 (0.51) DYRK1AMAP4K4MAP2K4GSK3AGSK3B
SCHEMBL4149348 0.81 CHEK1 (0.48) DYRK1AMAP4K4WNT1RIPK1KDR
SCHEMBL4149353 0.81 CHEK1 (0.48) DYRK1AMAP4K4WNT1RIPK1KDR
SCHEMBL2865663 0.80 DYRK1A (0.48) DYRK1AMAP4K4MAP2K4GSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
CN-1300116-C 1H-indazole compounds EISAI CO LTD (JP) 2007-02-14 CN disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
CN-1512987-A Novel 1H-indazole compound ������������ʽ���� 2004-07-14 CN disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 DYRK1A 1216/4885MAP4K4 63/4885MAP2K4 61/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 DYRK1A 2459/4885MAP4K4 63/4885MAP2K4 53/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 DYRK1A 1216/4885MAP4K4 63/4885MAP2K4 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.